ASLAN Pharmaceuticals Gains Third Pipeline Drug via Licensing Deal with Almirall
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 5 (Table of Contents)
Published: 28 May-2012
DOI: 10.3833/pdr.v2012.i5.1745 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Almirall has licensed global rights to its DHODH (dihydroorotate dehydrogenase) inhibitor LAS186323, which is currently in Phase I development for rheumatoid arthritis, to Singapore-based ASLAN Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS